Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

With the rapid clinical development of immune checkpoint inhibitors (ICIs), the standard of care in cancer management has evolved rapidly. However, immunotherapy is not currently beneficial for all patients. In addition to intrinsic tumor factors, other etiologies of resistance to ICIs arise from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnestein, Robby, Galland, Loïck, Kalfeist, Laura, Ghiringhelli, François, Ladoire, Sylvain, Limagne, Emeric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481153/
https://www.ncbi.nlm.nih.gov/pubmed/36117524
http://dx.doi.org/10.1080/2162402X.2022.2120676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481153/
https://www.ncbi.nlm.nih.gov/pubmed/36117524
http://dx.doi.org/10.1080/2162402X.2022.2120676

Ejemplares similares